Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 101 to 110 of 2443 total matches.
In Brief: OTC Ivermectin for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
IN BRIEF
OTC Ivermectin for Head Lice
1. MJ Chen and MD Creinin. Mifepristone with buccal ...
Topical ivermectin lotion 0.5% (Sklice, and generics),
which has been available by prescription since 2012,
is now FDA-approved for sale over the counter (OTC)
for treatment of head lice in patients ≥6 months old.
Ivermectin is also available by prescription as a 1%
cream (Soolantra) approved for topical treatment of
inflammatory lesions of rosacea and in oral tablets
(Stromectol, and generics) for treatment of various
parasitic infections.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):103-4 doi:10.58347/tml.2023.1679e | Show Introduction Hide Introduction
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
) and tisagenlecleucel (Kymriah)
are also FDA-approved for treatment of large B-cell
lymphoma.1
a lentiviral vector ...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5 doi:10.58347/tml.2023.1679f | Show Introduction Hide Introduction
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
)-negative, high-risk
early breast cancer who received prior neoadjuvant
or adjuvant chemotherapy.1 It had ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 19, 2023 (Issue 1679)
of nonmetastatic castration-resistant
prostate cancer (nmCRPC).1
MECHANISM OF ACTION — Androgen receptors ...
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The drug was previously approved for
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC).
Med Lett Drugs Ther. 2023 Jun 19;65(1679):e108 doi:10.58347/tml.2023.1679h | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
.1
Treatment of pain when it is still mild to moderate in
intensity improves headache response ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Comparison Table: Triptans for Migraine (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
6.25, 12.5 mg tabs
20, 40 mg tabs 2.5 mg tabs 1, 2.5 mg tabs 5, 10 mg tabs, ODTs Imitrex and generics ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
mg/day over 4 wks:
wk 1: 25 mg in the
evening;
wk 2: 25 mg in the
morning and evening;
wk 3: 25 ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2 doi:10.58347/tml.2023.1678c | Show Introduction Hide Introduction
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
or refractory follicular
lymphoma, a common subtype of non-Hodgkin's
lymphoma.1
Pronunciation Key ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Sotorasib (Lumakras) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
. Sotorasib is the
first KRAS inhibitor to be approved in the US.
chemotherapy and a programmed death 1 (PD ...
Sotorasib (Lumakras — Amgen), an oral KRAS
inhibitor, has received accelerated approval by the
FDA for treatment of KRAS G12C-mutated locally
advanced or metastatic non-small cell lung cancer
(NSCLC) in adults who received at least one prior
systemic therapy. Accelerated approval was based
on the overall response rate and duration of response.
KRAS mutations are found in 25-30% of non-squamous-cell NSCLC cases and the G12C mutation
is the most common KRAS mutation. Sotorasib is the
first KRAS inhibitor to be approved in the US.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e104-5 doi:10.58347/tml.2023.1678e | Show Introduction Hide Introduction
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
in 2017 for
treatment of relapsed or refractory B-cell precursor
ALL in patients ≤25 years old.1 ...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 doi:10.58347/tml.2023.1678f | Show Introduction Hide Introduction